Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Trevi Therapeutics, Inc. (TRVI)
|
Add to portfolio |
|
|
|
| Price: |
$0.78
| | Metrics |
| OS: |
63.9
|
M
| |
-29
|
% ROE
|
| Market cap: |
$49.7
|
M
| |
-33
|
% ROIC
|
|
Net cash:
|
$13.8
|
M
| |
$0.22
|
per share
|
|
EV:
|
$36
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($27.6)
|
M
| |
|
|
|
EBIT
|
($27.6)
|
M
| |
|
|
| EPS |
($0.34)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.1 |
| Revenue growth | | | | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 12.2 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -6.1 |
| Gross margin | | | | | | -100.0% |
| Research and development | 19.8 | 23.0 | 22.3 | 19.3 | 14.1 | |
| General and administrative | 10.1 | 9.5 | 10.2 | 7.3 | 4.3 | 2.1 |
| EBIT | -29.9 | -32.5 | -32.5 | -26.6 | -18.4 | -8.2 |
| EBIT margin | | | | | | -135.1% |
| Pre-tax income | -29.2 | -34.0 | -32.8 | -26.1 | -20.7 | -12.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 |
| Tax rate | 0.1% | 0.1% | 0.1% | 0.1% | 0.6% | 0.2% |
| Net income | -29.2 | -33.9 | -32.8 | -26.8 | -25.6 | -12.9 |
| Net margin | | | | | | -211.0% |
| |
| Diluted EPS | ($0.45) | ($1.49) | ($1.81) | ($2.28) | ($58.45) | ($29.80) |
| Shares outstanding (diluted) | 64.5 | 22.8 | 18.1 | 11.7 | 0.4 | 0.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|